Joe Galati, M.D.
Harvoni was was approved by the FDA last week, for the treatment of chronic hepatitis C. A fixed dose of Ledipasvir and Sofosbuvir, this is the first once daily, 2-drug therapy. Dr. Galati reviewed the dosing of Harvoni based on the presence or absence of cirrhosis, and whether you have been treated previously.
No comments:
Post a Comment